Protalix Of Israel Meets Second Setback In U.S. FDA Approval
This article was originally published in PharmAsia News
Executive Summary
Israel's Protalix Biotherapeutics experienced a new setback by the U.S. FDA when the agency ordered more data before approving its Gaucher's drug